ValuEngine downgraded shares of Constellation Pharmaceuticals (NASDAQ:CNST) from a hold rating to a sell rating in a report released on Tuesday morning, ValuEngine reports.
Several other analysts have also weighed in on the stock. Royal Bank of Canada started coverage on shares of Constellation Pharmaceuticals in a report on Wednesday, September 4th. They set an outperform rating and a $20.00 price objective for the company. Zacks Investment Research raised shares of Constellation Pharmaceuticals from a sell rating to a buy rating and set a $8.75 price objective for the company in a report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $16.35.
NASDAQ CNST opened at $12.73 on Tuesday. The firm has a market cap of $328.73 million, a price-to-earnings ratio of -2.55 and a beta of 4.88. The company has a 50 day moving average of $7.91 and a 200-day moving average of $9.68. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.44. Constellation Pharmaceuticals has a 1-year low of $4.01 and a 1-year high of $14.04.
Constellation Pharmaceuticals (NASDAQ:CNST) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.80) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.80). On average, analysts forecast that Constellation Pharmaceuticals will post -2.95 earnings per share for the current year.
In related news, major shareholder Group L. P. Column purchased 1,411,764 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was acquired at an average price of $8.50 per share, with a total value of $11,999,994.00. Also, Director Anthony B. Evnin purchased 2,823,529 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was bought at an average cost of $8.50 per share, with a total value of $23,999,996.50. Company insiders own 43.70% of the company’s stock.
Several institutional investors have recently modified their holdings of CNST. Acadian Asset Management LLC acquired a new stake in shares of Constellation Pharmaceuticals in the second quarter valued at approximately $61,000. Wells Fargo & Company MN increased its holdings in shares of Constellation Pharmaceuticals by 42.1% in the second quarter. Wells Fargo & Company MN now owns 13,937 shares of the company’s stock valued at $171,000 after purchasing an additional 4,132 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Constellation Pharmaceuticals in the second quarter valued at approximately $329,000. Alps Advisors Inc. acquired a new stake in shares of Constellation Pharmaceuticals in the second quarter valued at approximately $663,000. Finally, P.A.W. Capital Corp acquired a new stake in shares of Constellation Pharmaceuticals in the second quarter valued at approximately $1,474,000. 65.71% of the stock is owned by institutional investors and hedge funds.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Featured Story: The role of implied volatility with call option volume
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.